img

Global Vaccine Particulate Adjuvants Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Vaccine Particulate Adjuvants Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Vaccine Particulate Adjuvants report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Vaccine Particulate Adjuvants market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Infectious Diseases and Cancer are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Vaccine Particulate Adjuvants industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Vaccine Particulate Adjuvants key manufacturers include Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France), Agenus, Inc (US), Novavax, Inc (US), SPI Pharma, Inc (US), Invivogen (US), Avanti Polar Lipids, Inc (US) and MVP Laboratories, Inc (US), etc. Brenntag Biosector (Denmark), CSL Limited (Australia), SEPPIC (France) are top 3 players and held % sales share in total in 2022.
Vaccine Particulate Adjuvants can be divided into Oral, Subcutaneous, Intranasal and Intramuscular, etc. Oral is the mainstream product in the market, accounting for % sales share globally in 2022.
Vaccine Particulate Adjuvants is widely used in various fields, such as Infectious Diseases, Cancer and Others,, etc. Infectious Diseases provides greatest supports to the Vaccine Particulate Adjuvants industry development. In 2022, global % sales of Vaccine Particulate Adjuvants went into Infectious Diseases filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Vaccine Particulate Adjuvants market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Brenntag Biosector (Denmark)
CSL Limited (Australia)
SEPPIC (France)
Agenus, Inc (US)
Novavax, Inc (US)
SPI Pharma, Inc (US)
Invivogen (US)
Avanti Polar Lipids, Inc (US)
MVP Laboratories, Inc (US)
OZ Biosciences (France)
Segment by Type
Oral
Subcutaneous
Intranasal
Intramuscular
Intradermal
Others

Segment by Application


Infectious Diseases
Cancer
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Vaccine Particulate Adjuvants market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Vaccine Particulate Adjuvants, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Vaccine Particulate Adjuvants industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Vaccine Particulate Adjuvants in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Vaccine Particulate Adjuvants introduction, etc. Vaccine Particulate Adjuvants Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Vaccine Particulate Adjuvants market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Vaccine Particulate Adjuvants Market Overview
1.1 Vaccine Particulate Adjuvants Product Overview
1.2 Vaccine Particulate Adjuvants Market Segment by Type
1.2.1 Oral
1.2.2 Subcutaneous
1.2.3 Intranasal
1.2.4 Intramuscular
1.2.5 Intradermal
1.2.6 Others
1.3 Global Vaccine Particulate Adjuvants Market Size by Type
1.3.1 Global Vaccine Particulate Adjuvants Market Size Overview by Type (2018-2034)
1.3.2 Global Vaccine Particulate Adjuvants Historic Market Size Review by Type (2018-2024)
1.3.3 Global Vaccine Particulate Adjuvants Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Vaccine Particulate Adjuvants Sales Breakdown by Type (2018-2024)
1.4.2 Europe Vaccine Particulate Adjuvants Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Vaccine Particulate Adjuvants Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Vaccine Particulate Adjuvants Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Vaccine Particulate Adjuvants Sales Breakdown by Type (2018-2024)
2 Global Vaccine Particulate Adjuvants Market Competition by Company
2.1 Global Top Players by Vaccine Particulate Adjuvants Sales (2018-2024)
2.2 Global Top Players by Vaccine Particulate Adjuvants Revenue (2018-2024)
2.3 Global Top Players by Vaccine Particulate Adjuvants Price (2018-2024)
2.4 Global Top Manufacturers Vaccine Particulate Adjuvants Manufacturing Base Distribution, Sales Area, Product Type
2.5 Vaccine Particulate Adjuvants Market Competitive Situation and Trends
2.5.1 Vaccine Particulate Adjuvants Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Vaccine Particulate Adjuvants Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Particulate Adjuvants as of 2022)
2.7 Date of Key Manufacturers Enter into Vaccine Particulate Adjuvants Market
2.8 Key Manufacturers Vaccine Particulate Adjuvants Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Vaccine Particulate Adjuvants Status and Outlook by Region
3.1 Global Vaccine Particulate Adjuvants Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Vaccine Particulate Adjuvants Historic Market Size by Region
3.2.1 Global Vaccine Particulate Adjuvants Sales in Volume by Region (2018-2024)
3.2.2 Global Vaccine Particulate Adjuvants Sales in Value by Region (2018-2024)
3.2.3 Global Vaccine Particulate Adjuvants Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Vaccine Particulate Adjuvants Forecasted Market Size by Region
3.3.1 Global Vaccine Particulate Adjuvants Sales in Volume by Region (2024-2034)
3.3.2 Global Vaccine Particulate Adjuvants Sales in Value by Region (2024-2034)
3.3.3 Global Vaccine Particulate Adjuvants Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Vaccine Particulate Adjuvants by Application
4.1 Vaccine Particulate Adjuvants Market Segment by Application
4.1.1 Infectious Diseases
4.1.2 Cancer
4.1.3 Others
4.2 Global Vaccine Particulate Adjuvants Market Size by Application
4.2.1 Global Vaccine Particulate Adjuvants Market Size Overview by Application (2018-2034)
4.2.2 Global Vaccine Particulate Adjuvants Historic Market Size Review by Application (2018-2024)
4.2.3 Global Vaccine Particulate Adjuvants Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Vaccine Particulate Adjuvants Sales Breakdown by Application (2018-2024)
4.3.2 Europe Vaccine Particulate Adjuvants Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Vaccine Particulate Adjuvants Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Vaccine Particulate Adjuvants Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Vaccine Particulate Adjuvants Sales Breakdown by Application (2018-2024)
5 North America Vaccine Particulate Adjuvants by Country
5.1 North America Vaccine Particulate Adjuvants Historic Market Size by Country
5.1.1 North America Vaccine Particulate Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Vaccine Particulate Adjuvants Sales in Volume by Country (2018-2024)
5.1.3 North America Vaccine Particulate Adjuvants Sales in Value by Country (2018-2024)
5.2 North America Vaccine Particulate Adjuvants Forecasted Market Size by Country
5.2.1 North America Vaccine Particulate Adjuvants Sales in Volume by Country (2024-2034)
5.2.2 North America Vaccine Particulate Adjuvants Sales in Value by Country (2024-2034)
6 Europe Vaccine Particulate Adjuvants by Country
6.1 Europe Vaccine Particulate Adjuvants Historic Market Size by Country
6.1.1 Europe Vaccine Particulate Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Vaccine Particulate Adjuvants Sales in Volume by Country (2018-2024)
6.1.3 Europe Vaccine Particulate Adjuvants Sales in Value by Country (2018-2024)
6.2 Europe Vaccine Particulate Adjuvants Forecasted Market Size by Country
6.2.1 Europe Vaccine Particulate Adjuvants Sales in Volume by Country (2024-2034)
6.2.2 Europe Vaccine Particulate Adjuvants Sales in Value by Country (2024-2034)
7 Asia-Pacific Vaccine Particulate Adjuvants by Region
7.1 Asia-Pacific Vaccine Particulate Adjuvants Historic Market Size by Region
7.1.1 Asia-Pacific Vaccine Particulate Adjuvants Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Vaccine Particulate Adjuvants Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Vaccine Particulate Adjuvants Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Vaccine Particulate Adjuvants Forecasted Market Size by Region
7.2.1 Asia-Pacific Vaccine Particulate Adjuvants Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Vaccine Particulate Adjuvants Sales in Value by Region (2024-2034)
8 Latin America Vaccine Particulate Adjuvants by Country
8.1 Latin America Vaccine Particulate Adjuvants Historic Market Size by Country
8.1.1 Latin America Vaccine Particulate Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Vaccine Particulate Adjuvants Sales in Volume by Country (2018-2024)
8.1.3 Latin America Vaccine Particulate Adjuvants Sales in Value by Country (2018-2024)
8.2 Latin America Vaccine Particulate Adjuvants Forecasted Market Size by Country
8.2.1 Latin America Vaccine Particulate Adjuvants Sales in Volume by Country (2024-2034)
8.2.2 Latin America Vaccine Particulate Adjuvants Sales in Value by Country (2024-2034)
9 Middle East and Africa Vaccine Particulate Adjuvants by Country
9.1 Middle East and Africa Vaccine Particulate Adjuvants Historic Market Size by Country
9.1.1 Middle East and Africa Vaccine Particulate Adjuvants Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Vaccine Particulate Adjuvants Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Vaccine Particulate Adjuvants Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Vaccine Particulate Adjuvants Forecasted Market Size by Country
9.2.1 Middle East and Africa Vaccine Particulate Adjuvants Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Vaccine Particulate Adjuvants Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Brenntag Biosector (Denmark)
10.1.1 Brenntag Biosector (Denmark) Company Information
10.1.2 Brenntag Biosector (Denmark) Introduction and Business Overview
10.1.3 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Products Offered
10.1.5 Brenntag Biosector (Denmark) Recent Development
10.2 CSL Limited (Australia)
10.2.1 CSL Limited (Australia) Company Information
10.2.2 CSL Limited (Australia) Introduction and Business Overview
10.2.3 CSL Limited (Australia) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.2.4 CSL Limited (Australia) Vaccine Particulate Adjuvants Products Offered
10.2.5 CSL Limited (Australia) Recent Development
10.3 SEPPIC (France)
10.3.1 SEPPIC (France) Company Information
10.3.2 SEPPIC (France) Introduction and Business Overview
10.3.3 SEPPIC (France) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.3.4 SEPPIC (France) Vaccine Particulate Adjuvants Products Offered
10.3.5 SEPPIC (France) Recent Development
10.4 Agenus, Inc (US)
10.4.1 Agenus, Inc (US) Company Information
10.4.2 Agenus, Inc (US) Introduction and Business Overview
10.4.3 Agenus, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.4.4 Agenus, Inc (US) Vaccine Particulate Adjuvants Products Offered
10.4.5 Agenus, Inc (US) Recent Development
10.5 Novavax, Inc (US)
10.5.1 Novavax, Inc (US) Company Information
10.5.2 Novavax, Inc (US) Introduction and Business Overview
10.5.3 Novavax, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Novavax, Inc (US) Vaccine Particulate Adjuvants Products Offered
10.5.5 Novavax, Inc (US) Recent Development
10.6 SPI Pharma, Inc (US)
10.6.1 SPI Pharma, Inc (US) Company Information
10.6.2 SPI Pharma, Inc (US) Introduction and Business Overview
10.6.3 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.6.4 SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Products Offered
10.6.5 SPI Pharma, Inc (US) Recent Development
10.7 Invivogen (US)
10.7.1 Invivogen (US) Company Information
10.7.2 Invivogen (US) Introduction and Business Overview
10.7.3 Invivogen (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Invivogen (US) Vaccine Particulate Adjuvants Products Offered
10.7.5 Invivogen (US) Recent Development
10.8 Avanti Polar Lipids, Inc (US)
10.8.1 Avanti Polar Lipids, Inc (US) Company Information
10.8.2 Avanti Polar Lipids, Inc (US) Introduction and Business Overview
10.8.3 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Products Offered
10.8.5 Avanti Polar Lipids, Inc (US) Recent Development
10.9 MVP Laboratories, Inc (US)
10.9.1 MVP Laboratories, Inc (US) Company Information
10.9.2 MVP Laboratories, Inc (US) Introduction and Business Overview
10.9.3 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.9.4 MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Products Offered
10.9.5 MVP Laboratories, Inc (US) Recent Development
10.10 OZ Biosciences (France)
10.10.1 OZ Biosciences (France) Company Information
10.10.2 OZ Biosciences (France) Introduction and Business Overview
10.10.3 OZ Biosciences (France) Vaccine Particulate Adjuvants Sales, Revenue and Gross Margin (2018-2024)
10.10.4 OZ Biosciences (France) Vaccine Particulate Adjuvants Products Offered
10.10.5 OZ Biosciences (France) Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Vaccine Particulate Adjuvants Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Vaccine Particulate Adjuvants Industrial Chain Analysis
11.4 Vaccine Particulate Adjuvants Market Dynamics
11.4.1 Vaccine Particulate Adjuvants Industry Trends
11.4.2 Vaccine Particulate Adjuvants Market Drivers
11.4.3 Vaccine Particulate Adjuvants Market Challenges
11.4.4 Vaccine Particulate Adjuvants Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Vaccine Particulate Adjuvants Distributors
12.3 Vaccine Particulate Adjuvants Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Oral
Table 2. Major Company of Subcutaneous
Table 3. Major Company of Intranasal
Table 4. Major Company of Intramuscular
Table 5. Major Company of Intradermal
Table 6. Major Company of Others
Table 7. Global Vaccine Particulate Adjuvants Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (K Pcs)
Table 9. Global Vaccine Particulate Adjuvants Sales Market Share in Volume by Type (2018-2024)
Table 10. Global Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (US& Million)
Table 11. Global Vaccine Particulate Adjuvants Market Share in Value by Type (2018-2024)
Table 12. Global Vaccine Particulate Adjuvants Price by Type (2018-2024) & (USD/Pcs)
Table 13. Global Vaccine Particulate Adjuvants Sales by Type (2024-2034) & (K Pcs)
Table 14. Global Vaccine Particulate Adjuvants Sales Market Share in Volume by Type (2024-2034)
Table 15. Global Vaccine Particulate Adjuvants Sales by Type (2024-2034) & (US$ Million)
Table 16. Global Vaccine Particulate Adjuvants Sales Market Share in Value by Type (2024-2034)
Table 17. Global Vaccine Particulate Adjuvants Price by Type (2024-2034) & (USD/Pcs)
Table 18. North America Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (K Pcs)
Table 19. North America Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (US$ Million)
Table 20. Europe Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2018-2024)
Table 21. Europe Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (US$ Million)
Table 22. Asia-Pacific Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2018-2024)
Table 23. Asia-Pacific Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (US$ Million)
Table 24. Latin America Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2018-2024)
Table 25. Latin America Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (US$ Million)
Table 26. Middle East and Africa Vaccine Particulate Adjuvants Sales (K Pcs) by Type (2018-2024)
Table 27. Middle East and Africa Vaccine Particulate Adjuvants Sales by Type (2018-2024) & (US$ Million)
Table 28. Global Vaccine Particulate Adjuvants Sales by Company (2018-2024) & (K Pcs)
Table 29. Global Vaccine Particulate Adjuvants Sales Share by Company (2018-2024)
Table 30. Global Vaccine Particulate Adjuvants Revenue by Company (2018-2024) & (US$ Million)
Table 31. Global Vaccine Particulate Adjuvants Revenue Share by Company (2018-2024)
Table 32. Global Market Vaccine Particulate Adjuvants Price by Company (2018-2024) & (USD/Pcs)
Table 33. Global Vaccine Particulate Adjuvants Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 34. Global Vaccine Particulate Adjuvants Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 35. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Vaccine Particulate Adjuvants as of 2022)
Table 36. Date of Key Manufacturers Enter into Vaccine Particulate Adjuvants Market
Table 37. Key Manufacturers Vaccine Particulate Adjuvants Product Type
Table 38. Mergers & Acquisitions, Expansion Plans
Table 39. Global Vaccine Particulate Adjuvants Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 40. Global Vaccine Particulate Adjuvants Sales by Region (2018-2024) & (K Pcs)
Table 41. Global Vaccine Particulate Adjuvants Sales Market Share in Volume by Region (2018-2024)
Table 42. Global Vaccine Particulate Adjuvants Sales by Region (2018-2024) & (US$ Million)
Table 43. Global Vaccine Particulate Adjuvants Sales Market Share in Value by Region (2018-2024)
Table 44. Global Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 45. Global Vaccine Particulate Adjuvants Sales by Region (2024-2034) & (K Pcs)
Table 46. Global Vaccine Particulate Adjuvants Sales Market Share in Volume by Region (2024-2034)
Table 47. Global Vaccine Particulate Adjuvants Sales by Region (2024-2034) & (US$ Million)
Table 48. Global Vaccine Particulate Adjuvants Sales Market Share in Value by Region (2024-2034)
Table 49. Global Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 50. Global Vaccine Particulate Adjuvants Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 51. Global Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (K Pcs)
Table 52. Global Vaccine Particulate Adjuvants Sales Market Share in Volume by Application (2018-2024)
Table 53. Global Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (US$ Million)
Table 54. Global Vaccine Particulate Adjuvants Sales Market Share in Value by Application (2018-2024)
Table 55. Global Vaccine Particulate Adjuvants Price by Application (2018-2024) & (USD/Pcs)
Table 56. Global Vaccine Particulate Adjuvants Sales by Application (2024-2034) & (K Pcs)
Table 57. Global Vaccine Particulate Adjuvants Sales Market Share in Volume by Application (2024-2034)
Table 58. Global Vaccine Particulate Adjuvants Sales by Application (2024-2034) & (US$ Million)
Table 59. Global Vaccine Particulate Adjuvants Sales Market Share in Value by Application (2024-2034)
Table 60. Global Vaccine Particulate Adjuvants Price by Application (2024-2034) & (USD/Pcs)
Table 61. North America Vaccine Particulate Adjuvants Sales by Application (2018-2024) (K Pcs)
Table 62. North America Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (US$ Million)
Table 63. Europe Vaccine Particulate Adjuvants Sales by Application (2018-2024) (K Pcs)
Table 64. Europe Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (US$ Million)
Table 65. Asia-Pacific Vaccine Particulate Adjuvants Sales by Application (2018-2024) (K Pcs)
Table 66. Asia-Pacific Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (US$ Million)
Table 67. Latin America Vaccine Particulate Adjuvants Sales by Application (2018-2024) (K Pcs)
Table 68. Latin America Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (US$ Million)
Table 69. Middle East and Africa Vaccine Particulate Adjuvants Sales by Application (2018-2024) (K Pcs)
Table 70. Middle East and Africa Vaccine Particulate Adjuvants Sales by Application (2018-2024) & (US$ Million)
Table 71. North America Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (K Pcs)
Table 72. North America Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2018-2024)
Table 73. North America Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (US$ Million)
Table 74. North America Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2018-2024)
Table 75. North America Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (K Pcs)
Table 76. North America Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2024-2034)
Table 77. North America Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (US$ Million)
Table 78. North America Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2024-2034)
Table 79. Europe Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (K Pcs)
Table 80. Europe Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2018-2024)
Table 81. Europe Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (US$ Million)
Table 82. Europe Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2018-2024)
Table 83. Europe Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (K Pcs)
Table 84. Europe Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2024-2034)
Table 85. Europe Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (US$ Million)
Table 86. Europe Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2024-2034)
Table 87. Asia-Pacific Vaccine Particulate Adjuvants Sales by Region (2018-2024) & (K Pcs)
Table 88. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Volume by Region (2018-2024)
Table 89. Asia-Pacific Vaccine Particulate Adjuvants Sales by Region (2018-2024) & (US$ Million)
Table 90. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Value by Region (2018-2024)
Table 91. Asia-Pacific Vaccine Particulate Adjuvants Sales by Region (2024-2034) & (K Pcs)
Table 92. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Volume by Region (2024-2034)
Table 93. Asia-Pacific Vaccine Particulate Adjuvants Sales by Region (2024-2034) & (US$ Million)
Table 94. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Value by Region (2024-2034)
Table 95. Latin America Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (K Pcs)
Table 96. Latin America Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2018-2024)
Table 97. Latin America Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (US$ Million)
Table 98. Latin America Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2018-2024)
Table 99. Latin America Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (K Pcs)
Table 100. Latin America Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2024-2034)
Table 101. Latin America Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (US$ Million)
Table 102. Latin America Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2024-2034)
Table 103. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (K Pcs)
Table 104. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2018-2024)
Table 105. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2018-2024) & (US$ Million)
Table 106. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2018-2024)
Table 107. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (K Pcs)
Table 108. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Volume by Country (2024-2034)
Table 109. Middle East and Africa Vaccine Particulate Adjuvants Sales by Country (2024-2034) & (US$ Million)
Table 110. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Value by Country (2024-2034)
Table 111. Brenntag Biosector (Denmark) Company Information
Table 112. Brenntag Biosector (Denmark) Introduction and Business Overview
Table 113. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 114. Brenntag Biosector (Denmark) Vaccine Particulate Adjuvants Product
Table 115. Brenntag Biosector (Denmark) Recent Development
Table 116. CSL Limited (Australia) Company Information
Table 117. CSL Limited (Australia) Introduction and Business Overview
Table 118. CSL Limited (Australia) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 119. CSL Limited (Australia) Vaccine Particulate Adjuvants Product
Table 120. CSL Limited (Australia) Recent Development
Table 121. SEPPIC (France) Company Information
Table 122. SEPPIC (France) Introduction and Business Overview
Table 123. SEPPIC (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 124. SEPPIC (France) Vaccine Particulate Adjuvants Product
Table 125. SEPPIC (France) Recent Development
Table 126. Agenus, Inc (US) Company Information
Table 127. Agenus, Inc (US) Introduction and Business Overview
Table 128. Agenus, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 129. Agenus, Inc (US) Vaccine Particulate Adjuvants Product
Table 130. Agenus, Inc (US) Recent Development
Table 131. Novavax, Inc (US) Company Information
Table 132. Novavax, Inc (US) Introduction and Business Overview
Table 133. Novavax, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 134. Novavax, Inc (US) Vaccine Particulate Adjuvants Product
Table 135. Novavax, Inc (US) Recent Development
Table 136. SPI Pharma, Inc (US) Company Information
Table 137. SPI Pharma, Inc (US) Introduction and Business Overview
Table 138. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 139. SPI Pharma, Inc (US) Vaccine Particulate Adjuvants Product
Table 140. SPI Pharma, Inc (US) Recent Development
Table 141. Invivogen (US) Company Information
Table 142. Invivogen (US) Introduction and Business Overview
Table 143. Invivogen (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 144. Invivogen (US) Vaccine Particulate Adjuvants Product
Table 145. Invivogen (US) Recent Development
Table 146. Avanti Polar Lipids, Inc (US) Company Information
Table 147. Avanti Polar Lipids, Inc (US) Introduction and Business Overview
Table 148. Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 149. Avanti Polar Lipids, Inc (US) Vaccine Particulate Adjuvants Product
Table 150. Avanti Polar Lipids, Inc (US) Recent Development
Table 151. MVP Laboratories, Inc (US) Company Information
Table 152. MVP Laboratories, Inc (US) Introduction and Business Overview
Table 153. MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 154. MVP Laboratories, Inc (US) Vaccine Particulate Adjuvants Product
Table 155. MVP Laboratories, Inc (US) Recent Development
Table 156. OZ Biosciences (France) Company Information
Table 157. OZ Biosciences (France) Introduction and Business Overview
Table 158. OZ Biosciences (France) Vaccine Particulate Adjuvants Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 159. OZ Biosciences (France) Vaccine Particulate Adjuvants Product
Table 160. OZ Biosciences (France) Recent Development
Table 161. Key Raw Materials Lists
Table 162. Raw Materials Key Suppliers Lists
Table 163. Vaccine Particulate Adjuvants Market Trends
Table 164. Vaccine Particulate Adjuvants Market Drivers
Table 165. Vaccine Particulate Adjuvants Market Challenges
Table 166. Vaccine Particulate Adjuvants Market Restraints
Table 167. Vaccine Particulate Adjuvants Distributors List
Table 168. Vaccine Particulate Adjuvants Downstream Customers
Table 169. Research Programs/Design for This Report
Table 170. Key Data Information from Secondary Sources
Table 171. Key Data Information from Primary Sources
List of Figures
Figure 1. Vaccine Particulate Adjuvants Product Picture
Figure 2. Global Vaccine Particulate Adjuvants Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Vaccine Particulate Adjuvants Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Vaccine Particulate Adjuvants Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Oral
Figure 6. Global Oral Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Subcutaneous
Figure 8. Global Subcutaneous Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Intranasal
Figure 10. Global Intranasal Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Intramuscular
Figure 12. Global Intramuscular Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Intradermal
Figure 14. Global Intradermal Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Others
Figure 16. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Global Vaccine Particulate Adjuvants Sales by Type (2018-2034) & (US$ Million)
Figure 18. Global Vaccine Particulate Adjuvants Sales Market Share by Type in 2022 & 2034
Figure 19. North America Vaccine Particulate Adjuvants Sales Market Share in Volume by Type in 2022
Figure 20. North America Vaccine Particulate Adjuvants Sales Market Share in Value by Type in 2022
Figure 21. Europe Vaccine Particulate Adjuvants Sales Market Share in Volume by Type in 2022
Figure 22. Europe Vaccine Particulate Adjuvants Sales Market Share in Value by Type in 2022
Figure 23. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Volume by Type in 2022
Figure 24. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Value by Type in 2022
Figure 25. Latin America Vaccine Particulate Adjuvants Sales Market Share in Volume by Type in 2022
Figure 26. Latin America Vaccine Particulate Adjuvants Sales Market Share in Value by Type in 2022
Figure 27. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Volume by Type in 2022
Figure 28. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Value by Type in 2022
Figure 29. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine Particulate Adjuvants Sales in 2022
Figure 30. The 5 and 10 Largest Manufacturers in the World: Market Share by Vaccine Particulate Adjuvants Revenue in 2022
Figure 31. Vaccine Particulate Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Product Picture of Infectious Diseases
Figure 33. Global Infectious Diseases Sales YoY Growth (2018-2034) & (K Pcs)
Figure 34. Product Picture of Cancer
Figure 35. Global Cancer Sales YoY Growth (2018-2034) & (K Pcs)
Figure 36. Product Picture of Others
Figure 37. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Global Vaccine Particulate Adjuvants Sales by Application (2018-2034) & (US$ Million)
Figure 39. Global Vaccine Particulate Adjuvants Sales Market Share by Application in 2022 & 2034
Figure 40. North America Vaccine Particulate Adjuvants Sales Market Share in Volume by Application in 2022
Figure 41. North America Vaccine Particulate Adjuvants Sales Market Share in Value by Application in 2022
Figure 42. Europe Vaccine Particulate Adjuvants Sales Market Share in Volume by Application in 2022
Figure 43. Europe Vaccine Particulate Adjuvants Sales Market Share in Value by Application in 2022
Figure 44. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Volume by Application in 2022
Figure 45. Asia-Pacific Vaccine Particulate Adjuvants Sales Market Share in Value by Application in 2022
Figure 46. Latin America Vaccine Particulate Adjuvants Sales Market Share in Volume by Application in 2022
Figure 47. Latin America Vaccine Particulate Adjuvants Sales Market Share in Value by Application in 2022
Figure 48. Middle East and Africa Vaccine Particulate Adjuvants Sales Market Share in Value by Application in 2022
Figure 49. Key Raw Materials Price
Figure 50. Vaccine Particulate Adjuvants Manufacturing Cost Structure
Figure 51. Vaccine Particulate Adjuvants Industrial Chain Analysis
Figure 52. Channels of Distribution
Figure 53. Distributors Profiles
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries